RESUMO
The tissue-protective action of erythropoietin (EPO) in animal models is often associated with reduced inflammation. However, there are many contrasting reports of the effect of EPO on the production of inflammatory cytokines induced by lipopolysaccharide (LPS) in vitro, with different papers reporting an inhibition, an upregulation, or a lack of effect. Negative results are likely underestimated by a publication bias. As EPO has anti-inflammatory actions in models associated with tissue injury, we hypothesized that EPO could specifically inhibit the induction of inflammatory cytokines by danger signals associated with cell death, and investigated its effect on the induction of IL-6 or TNF by high-mobility group-box 1 protein (HMGB1) or by necrotic cells. We did not observe any significant effect of EPO in these models; neither EPO affected the response induced by TLR agonists different from LPS, or by extracellular ATP-mediated activation of the inflammasome. We conclude that the inhibition of inflammation by EPO is likely to be an indirect effect, secondary to its tissue-protective activity, or that it requires a prior priming induced by the injury.
Assuntos
Eritropoetina/farmacologia , Interleucina-6/biossíntese , Fator de Necrose Tumoral alfa/biossíntese , Trifosfato de Adenosina/farmacologia , Animais , Extratos Celulares , Proteína HMGB1/farmacologia , Humanos , Inflamassomos/metabolismo , Interleucina-1beta/metabolismo , Lipopolissacarídeos/farmacologia , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Masculino , Camundongos , NecroseRESUMO
Studies on the neuritis model suggest that in many patients with neuropathic pain, symptoms may be due to nerve inflammation rather than frank nerve injury. Treatments for these patients are often ineffective. The neuroprotective and hematopoietic agent erythropoietin (EPO) has been shown to reverse pain behaviors in nerve injury models and therefore may be of therapeutic benefit. However, EPO can cause thrombosis. ARA290 is an analog of EPO that has the neuroprotective activities of EPO without stimulating hematopoiesis. The present study has examined the effects of ARA290 on pain behavior in the neuritis model. Following neuritis induction, 30 or 120 µg/kg ARA290 or saline vehicle was injected intraperitoneally into rats daily from day 1 post surgery. Animals were assessed for mechanical allodynia and heat hyperalgesia. Levels of the cytokine tumor necrosis factor-α (TNF-α) and chemokine (CC motif) ligand 2 (CCL2) mRNA were also assessed using polymerase chain reaction. Vehicle-treated neuritis animals (n=20) developed signs of mechanical allodynia and heat hyperalgesia that reached a maximum on day 4 and 3 of testing, respectively. Treatment with either 30 (n=11) or 120 µg/kg ARA290 (n=9) prevented the development of mechanical allodynia. However, ARA290 did not significantly affect heat hyperalgesia. There was no significant difference between the effects of each drug dose (p<0.05, unpaired t test comparing area under the curve for mechanical allodynia). The levels of CCL2 and TNF-α mRNA in the nerve and Gelfoam were not significantly different following 120 µg/kg ARA290 treatment (n=3-7) compared to vehicle-treated animals (n=3-7; p=0.24; unpaired t tests). In summary, ARA290 may be beneficial in the treatment of neuropathic pain symptoms where signs of nerve injury are absent on clinical assessment. The mechanisms of action do not appear to involve the inhibition of TNF-α or CCL2 production.
Assuntos
Eritropoetina/análogos & derivados , Hiperalgesia/tratamento farmacológico , Neurite (Inflamação)/tratamento farmacológico , Fármacos Neuroprotetores/uso terapêutico , Oligopeptídeos/uso terapêutico , Nervo Isquiático/fisiopatologia , Animais , Quimiocina CCL2/efeitos dos fármacos , Quimiocina CCL2/genética , Quimiocina CCL2/metabolismo , Modelos Animais de Doenças , Eritropoetina/uso terapêutico , Hiperalgesia/etiologia , Masculino , Neuralgia/tratamento farmacológico , Neuralgia/etiologia , Neuralgia/patologia , Neurite (Inflamação)/complicações , Neurite (Inflamação)/patologia , RNA Mensageiro/análise , Ratos , Ratos Sprague-Dawley , Nervo Isquiático/efeitos dos fármacos , Nervo Isquiático/metabolismo , Nervo Isquiático/patologia , Fator de Necrose Tumoral alfa/efeitos dos fármacos , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/metabolismoRESUMO
1-[(2-adamantyl)amino]acetyl-2-cyano-(S)-pyrrolidine, monohydrochloride (PKF275-055), a vildagliptin analog, is a novel, selective, potent, orally bioavailable, and long-acting dipeptidyl peptidase IV inhibitor. We studied the effect of PKF275-055 administration on the prevention, protection, and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. PKF275-055 improved body and muscle weight. Oral glucose tolerance tests showed a marked improvement in glucose metabolism under all treatment schedules. When tested in prevention and protection experiments, PKF275-055 completely averted the decrease of Naâº/Kâº-ATPase activity and partially counteracted the nerve conduction velocity (NCV) deficit observed in untreated diabetic rats but had no effects on abnormal mechanical and thermal sensitivity. When used in a therapeutic setting, PKF275-055 induced a significant correction in the alteration in Naâº,Kâº-ATPase activity and NCV present in untreated diabetics. Diabetic rats developed mechanical hyperalgesia within 2 weeks after streptozotocin injection and exhibited significantly longer thermal response latencies. It is noteworthy that PKF275-055 treatment restored mechanical sensitivity thresholds by approximately 50% (p < 0.01) and progressively improved the alteration in thermal responsiveness. In conclusion, PKF275-055 showed an anabolic effect, improved oral glucose tolerance, and counteracted the alterations in Naâº,Kâº-ATPase activity, NCV, and nociceptive thresholds in diabetic rats. The present data support a potential therapeutic effect of PKF275-055 in the treatment of rodent diabetic neuropathy.
Assuntos
Adamantano/análogos & derivados , Diabetes Mellitus Experimental/complicações , Neuropatias Diabéticas/tratamento farmacológico , Inibidores da Dipeptidil Peptidase IV/farmacologia , Nitrilas/farmacologia , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Pirrolidinas/farmacologia , Adamantano/química , Adamantano/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Progressão da Doença , Relação Dose-Resposta a Droga , Ingestão de Líquidos/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Teste de Tolerância a Glucose , Masculino , Condução Nervosa/efeitos dos fármacos , Nitrilas/química , Limiar da Dor/efeitos dos fármacos , Pirrolidinas/química , Ratos , Ratos Sprague-Dawley , ATPase Trocadora de Sódio-Potássio/metabolismo , VildagliptinaRESUMO
BACKGROUND: Hemofiltrate reinfusion (HFR) is a form of hemodiafiltration (HDF) in which replacement fluid is constituted by ultrafiltrate from the patient 'regenerated' through a cartridge containing hydrophobic styrene resin. Bicarbonate-based dialysis solutions (DS) used in routine hemodialysis and HDF contain small quantities of acetate (3-5 mM) as a stabilizing agent, one of the major causes of intradialytic hypotension. Acetate-free (AF) DS have recently been made available, substituting acetate with hydrochloric acid. The impact of AF DS during HFR on Hb levels and erythropoietic-stimulating agent (ESA) requirement in chronic dialysis patients was assessed. PATIENTS AND METHODS: After obtaining informed consent, 30 uremic patients treated by standard bicarbonate dialysis (BHD, DS with acetate) were randomized to treatment in 3-month cycles: first AF HFR, followed by HFR with acetate, and again AF HFR. At the beginning and end of each period, Hb and ESA requirements were evaluated. RESULTS: A significant increase in the Hb level was observed throughout all periods of HFR versus BHD (from 11.1 to 11.86 g/dl; p = 0.04), with a significant decrease of ESA requirements from 29,500 to 25,033 IU/month (p = 0.04). CONCLUSION: Regardless of the presence or absence of acetate in DS, HFR per se allows a significant lowering of ESA dosage versus BHD, while at the same time increasing Hb levels. Taking for granted the clinical impact produced, HFR seems to provide a relevant decrease in end-stage renal disease patient costs.
Assuntos
Eritropoetina/uso terapêutico , Hematínicos/uso terapêutico , Hemodiafiltração , Soluções para Hemodiálise/uso terapêutico , Uremia/terapia , Idoso , Idoso de 80 Anos ou mais , Citocinas/uso terapêutico , Suplementos Nutricionais , Feminino , Hemoglobinas/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Uremia/economia , Uremia/metabolismo , Vitaminas/uso terapêuticoRESUMO
AIM: The purpose of the study was to examine the effect of hemodiafiltration with endogenous reinfusion (HFR) compared to hemodialysis (HD) on 28 uremic patients with secondary hyperparathyroidism (2HPT) but positively selected for good and stable control of phosphatemia in order to evaluate the independent effects of dialysis treatments on bone turnover metabolism. METHODS: The study was divided into 3 periods of observation: a) HD for three months; b) HFR for three months; c) HFR for a further 3 months. We analysed the trend of: whole PTH, 1-84 PTH, 7-84 PTH, alkaline phosphatase and its bone isoenzyme, total and ionised calcium, phosphatemia, dose of phosphate binder agents, beta2-microglobulin, CRP. All the variations found were evaluated through mean values +/- SD, t-tests, multivariate analysis. RESULTS: We observed a deceleration in bone turnover characterized by a reduction of the total and bone alkaline phosphatase (IU/mL) from 92.3 +/- 82.8 and 35.8 +/- 49.8 at the end of HD to 63.4 +/- 23.9 and 16.0 +/- 8.7 at the end of HFR, respectively, and 1-84 PTH from 317.5 +/- 264.6 pg/mL at the end of HD to 287.5 +/- 258.9 pg/mL at the end of the 3rd month of HFR. Beta2-microglobulin was reduced from 32.9 +/- 16.1 mg/L at the end of HD to 26.4 +/- 8.1 mg/L already at the end of the first three months of HFR. CRP was reduced from 2.5 +/- 2.6 mg/dL at the beginning of the study to 1.3 +/- 1.7 mg/dL at the end of HFR. There were no differences with regard to: dialytic efficiency, nutritional status, calcemia, phosphatemia (maintained in the K-DOQI range for the entire duration of the study), also thanks to more careful use of phosphate chelating agents. CONCLUSION: We are of the opinion that HFR - essentially thanks to the use of ultrapure endogenous infusate - induces a deceleration in bone turnover due to 2PHT. In addition, phosphate subtraction in HFR is better compared to HD, thanks to the improvement of the anti-inflammatory conditions by removing the cytokines harmful to bone metabolism and excluding a priori the negative effects related to hyperphosphatemia.
Assuntos
Cálcio/metabolismo , Hemodiafiltração/métodos , Sistemas On-Line , Fósforo/metabolismo , Uremia/metabolismo , Uremia/terapia , Idoso , Fosfatase Alcalina/metabolismo , Proteína C-Reativa/metabolismo , Distúrbio Mineral e Ósseo na Doença Renal Crônica/metabolismo , Feminino , Humanos , Hiperparatireoidismo Secundário/metabolismo , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estado Nutricional , Resultado do Tratamento , Microglobulina beta-2/metabolismoRESUMO
AIM: The purpose of this study was to optimize the operative and analytical methodologies to a more exact determination of intradialytic kinetics of the phosphates (P) tested in hemodialysis (HD) and in on-line hemodiafiltration with endogenous reinfusion (HFR - Hemo Filtrate Reinfusion). METHODS: The mass balance measurements of urea and P were carried out in 18 clinically stable HD patients. The effective blood flow (Qb) was measured with a Transonic monitor. The plasma was deproteinized with 10% trichloroacetic acid to prevent breakdown of the proteins and the consequent pseudohyperphosphatemia. Subsequently the supernatant containing the ultrafiltrable phosphates was made to react with a solution of ammonium molybdate for a spectrophotometric reading. RESULTS: The mean urea mass transfer in HD was 16.9 g/session and in HFR 15.4 g/session. The mean P mass transfer in HD was 726 mg/session and in HFR 679 mg/session. Nevertheless, in HFR a significant difference was verified between the clearances of P, between the plasma water side (122.4 +/- 30.8 ml/min) and the dialysate side (105.9 +/- 19.4 ml/min). CONCLUSION: As far as the P mass transfer is concerned, the data obtained is able to be superimposed with that described in the literature during HD, while in HFR it is possible to hypothesize a high efficiency, thanks to an increased output of P in relation to the phenomenon of adsorption which, although is limited, contributes to the transfer of the total mass. Based on this study and re-examining the literature on P kinetics, there is space for methodological improvement both on the operating front with careful determination of the effective Qb, and on the chemical front overcoming the inaccuracy of automatic analyzers in determining the plasma P owing to possible overestimation of phosphatemia and poor sensitivity in measuring the lower levels of P present in the dialysate and/or ultrafiltrate.
Assuntos
Hemodiafiltração/métodos , Fosfatos/sangue , Diálise Renal , Uremia/sangue , Uremia/terapia , Feminino , Soluções para Hemodiálise/administração & dosagem , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Fatores de TempoRESUMO
Protein cysteines can undergo various forms of oxidation, some of them reversible (disulphide formation, glutathionylation and S-nitrosylation). While in the past these were viewed as protein damage in the context of oxidative stress, there is growing interest in oxidoreduction of protein thiols/disulphides as a regulatory mechanism. This review discusses the evolution of the concept of redox regulation from that of oxidative stress and the redox state of protein cysteines in different cellular compartments.
Assuntos
Proteínas/química , Compostos de Sulfidrila/química , Antioxidantes , Cisteína/química , Dissulfetos/química , Glutarredoxinas , Glutationa/metabolismo , Oxirredução , Estresse Oxidativo , Oxirredutases/metabolismo , Tiorredoxinas/metabolismoRESUMO
During hemodiafiltration (HDF) the increase in the ultrafiltration (uf) rate improves solute convective clearance. Therefore, considerable amounts of reinfusion liquid are necessary, whose quality must be guaranteed. The use of bags or bottles manufactured by industry causes many problems concerning handling (storage, repeated connections) and costs, and last but not least, it exposes the circuits to a contamination risk. Therefore, the technological research into on-line production systems of sterile and ultrapure reinfusion solutions is justified. The increasing interest in the on-line production of reinfusion fluids from the dialysing solution dates back to the 1990s, and the data in the literature are statistically positive concerning the improvement in depurative performances connected to the uf increase. Although, to be objective, a problem still exists, in real-time the absolute guarantee of the sterility and apirogenicity of the solutions produced on-line is impossible. Using a two-chamber filter, it is possible to produce reinfusion fluid from the uf of the patient himself, which has been 'regenerated' by a sorbent bed, in a closed circuit. This action eliminates any sterility problems, whilst, in addition, providing the possibility for good substance reinfusion such bicarbonates and essential and branched-chain aminoacids. This HDF method, hemo-filtrate-reinfusion (HFR), has clinically demonstrated, beyond its ease of execution, a reduction in physiological component loss, a high biocompatibility and an overall action in contrast to MIA syndrome factors, i.e. malnutrition, inflammation and atherosclerosis.
Assuntos
Hemodiafiltração/métodos , Soluções para Hemodiálise/administração & dosagem , HumanosRESUMO
AIMS: All convective hemodiafiltration techniques require a replacement fluid, which must have an adequate electrolytic composition and must be sterile and pyrogen-free. Using an integrated adsorption cartridge, the ultrafiltrate can be "regenerated" and used as a replacement fluid (hemo-filtrate reinfusion; HFR). The aim of this study was to evaluate whether the HFR technique as suggested in its original configuration could be improved by inverting the purification sequence (post-dilution HFR; PDHFR) in order to increase the purification efficiency of the whole system. METHODS: We performed standard HFR in 6 uremic patients during 6 months and, subsequently, during further 6 months, PDHFR. The dialytic efficacy of the two techniques and the filter blood loss were evaluated. Moreover, we studied how both techniques affected cytokine levels. RESULTS: We observed a significant increase of urea extraction and of Kt/V values in PDHFR. An equally significant improvement was observed in regard to the extraction of beta2-m and the blood loss. Furthermore, IL6 and TNFalpha decreased significantly after PDHFR treatment. CONCLUSIONS: HFR has proven to be an easy-to-perform hemodiafiltration technique, capable of resolving the typical problem of the other hemodiafiltration technique, the availability and production of a sterile and ultrapure reinfusion solution. The inversion of its configuration has allowed us to improve three aspects that have characterized, in our experience, the treatments performed in the original geometry: the removal of both urea and beta2-m, and the filter. Finally, it's notable that the decrease in cytokines levels achieved with PDHFR might attenuate the uremic micro-inflammatory state.
Assuntos
Hemodiafiltração/métodos , Soluções para Hemodiálise/administração & dosagem , Uremia/terapia , Adulto , Idoso , Citocinas/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Ureia/sangue , Uremia/sangue , Microglobulina beta-2/sangueRESUMO
Erythropoietin (EPO) increases the number of circulating erythrocytes primarily by preventing apoptosis of erythroid progenitors. In addition to this proerythroid action, results of recent studies show that systemically administered EPO is protective in vivo, in several animal models of neuronal injury. In vitro, EPO prevents neuronal apoptosis induced by a variety of stimuli. This review summarizes the neuroprotective actions of EPO and discusses the underlying mechanisms in terms of signal transduction pathways involved. The understanding of these mechanisms will help differentiate the neuroprotective actions of EPO from its role in the bone marrow.
Assuntos
Apoptose/fisiologia , Citoproteção/fisiologia , Eritropoetina/fisiologia , Animais , Anti-Inflamatórios/farmacologia , Apoptose/efeitos dos fármacos , Citocinas/fisiologia , Proteínas de Ligação a DNA/fisiologia , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/fisiologia , Células Epiteliais/efeitos dos fármacos , Eritropoetina/farmacologia , Eritropoetina/uso terapêutico , Hematopoese/fisiologia , Humanos , Fator 1 Induzível por Hipóxia , Subunidade alfa do Fator 1 Induzível por Hipóxia , Inflamação/tratamento farmacológico , Inflamação/fisiopatologia , Túbulos Renais/citologia , Túbulos Renais/efeitos dos fármacos , Modelos Biológicos , Isquemia Miocárdica/tratamento farmacológico , Neurônios/efeitos dos fármacos , Neurônios/fisiologia , Fármacos Neuroprotetores/farmacologia , Proteínas Nucleares/fisiologia , Transdução de Sinais/fisiologia , Fatores de Transcrição/fisiologia , Traumatismos do Sistema Nervoso/tratamento farmacológicoRESUMO
Oxidative stress is implicated in the pathogenesis of pulmonary damage during viral infections. In a previous study we observed a significant improvement of survival of influenza-infected mice with NAC, 1g/kg divided in two daily administrations, for 8 days including a pretreatment on day 1 before infection. In order to test NAC in a more realistic model, we studied the effect of combined treatment with NAC and the antiviral drug, ribavirin. Since in the present work we wanted to test a possible synergistic effect by combination of NAC and ribavirin, we used a different NAC's treatment regimen (1 g/kg, once a day for 4 days) that, alone, did not significantly protect mice from death. Mice (12 per group) infected intranasally with a lethal dose of influenza A virus APR/8. NAC was given as a single daily dose of 1000 mg/kg starting from 4 h after infection and until day 4 after infection, in association with ribavirin (100 mg/kg, i.p.). End-point evaluation was 14-day survival. With this schedule survival in infected mice was 17%, it was not significantly changed by NAC (25%). Survival increased to 58% with ribavirin and to 92% (n=12) with a combined treatment with ribavirin and NAC. This suggest that antioxidant therapy can increase survival by either improving the defenses against virus or by protecting from the pathogenesis of lung inflammation.
Assuntos
Acetilcisteína/uso terapêutico , Infecções por Orthomyxoviridae/mortalidade , Infecções por Orthomyxoviridae/prevenção & controle , Ribavirina/uso terapêutico , Animais , Modelos Animais de Doenças , Sinergismo Farmacológico , Vírus da Influenza A/efeitos dos fármacos , Vírus da Influenza A/imunologia , Masculino , Camundongos , Infecções por Orthomyxoviridae/tratamento farmacológico , Taxa de SobrevidaRESUMO
PURPOSE: Hemodiafiltration reinfusion (HFR) is characterized by the use of regenerated ultrafiltrate as replacement fluid. We devised a new technique, post-dilution HFR, aimed at increasing the purification efficiency, treatment tolerability and at reducing inflammatory state. METHODS: We performed post-dilution HFR in six uremic patients during 18 months. Dialytic efficacy, filter blood rest and cytokine behavior were evaluated. RESULTS: Neither pyrogenic reactions nor other adverse phenomena were recorded. The tolerance to the treatment was excellent. We observed a high rate of urea extraction and optimal Kt/V values, a high extraction of beta2 microglobulin (beta2-m) and a reduction in blood rest; in addition, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) significantly decreased. CONCLUSIONS. The inversion of the standard HFR configuration allowed us to improve the removal of both urea and beta2-m, and the blood rest, with an optimal tolerability. Moreover, the reduction in cytokine levels could attenuate the uremic microinflammatory state.
Assuntos
Hemodiafiltração/métodos , Soluções para Hemodiálise/administração & dosagem , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de TempoRESUMO
PURPOSE: Among hemodiafiltration (HFD) techniques, hemodiafiltration reinfusion (HFR) seems unable to achieve an optimal depurative efficacy. This study aimed to evaluate whether the HFR technique as suggested in its original configuration could be improved by devising a new technique (post-dilution HFR (PDHFR)) inverting the purification sequence to increase the purification efficiency of the entire system. METHODS: We performed standard HFR in six uremic patients during 6 months and, subsequently, during a further 6 months, PDHFR was performed. The dialytic efficacy of the two techniques and the filter blood rest were evaluated. In addition, we studied the behavior of cytokines during the inverted HFR sessions. RESULTS: We observed a significant increase in urea extraction and in Kt/V. An equally significant improvement was observed with regard to beta2-microglobulin (beta2-m) extraction and blood rest. Furthermore, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) significantly decreased after inverted HFR treatment. CONCLUSIONS: The inversion of the original configuration allowed us to improve the depurative efficacy of standard HFR, increasing the removal of both urea and beta2-m, and reducing the blood rest. Finally, it was notable that the reduction in cytokine levels could attenuate the uremic microinflammatory state.
Assuntos
Hemodiafiltração/métodos , Soluções para Hemodiálise/administração & dosagem , Uremia/terapia , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
PURPOSE: Hemodiafiltration (HDF) has high removal rates of low and middle-high molecular weight uremic toxins. We aimed to understand the efficacy and the safety in correcting on-line HDF acidosis. We compared two infusion methods of on-line prepared solution in HDF: HDF with an infusion solution produced from dialysate (HDF-OL) and HDF with a solution from patient ultrafiltrate after regeneration (HFR). METHODS: Eleven patients (four males, seven females) age 66 +/- 10 yrs, dialysis age 5.0 +/- 1.3 yrs, on anuria had two dialysis methods for the 1st session of the week, one HDF-OL and one HFR in 2 different weeks. In HDF-OL a high-flux polysulphone dialyser 1.8 m2 was used, in HFR a two-stage filter was used: polyetersulfone 0.7 m2 + SMC 1.95 m2 and a sorbent cartridge Selecta plus (Bellco) to regenerate the ultrafiltrate. HCO3- in the dialysis bath was 32 mmol/L. RESULTS: Plasma bicarbonates, before dialysis were 21.6 +/- 2.1 mmol/L on HDF-OL and 21.5 +/- 3.3 on HFR (p=ns), at the end they were 27.5 +/- 1.8 mmol/L on HDF-OL and 27.8 +/- 1.2 mmol/L on HFR (p=ns). On HDF-OL bicarbonates reached a plateau at mid session: 27 +/- 1.2, 27.5 +/- 1.2, 27.5 +/- 1.8 to 120, 180 and 240 min respectively. On HFR the plateau was reached more slowly: 26.1 +/- 1.9, 27.1 +/- 1.4, 27.8 +/- 1.2 with the same times. CONCLUSIONS: HFR-OL and HFR efficaciously corrected acidosis in a 4-h dialysis session. The same results, statistically and clinically, were achieved with infusion solution derived from dialysate and from solution from regenerated ultrafiltrate. In the latter, it was interesting that the global quality of the infusion solution was obtained from a close circuit from the patient ultrafiltrate.
Assuntos
Bicarbonatos/sangue , Hemodiafiltração/métodos , Soluções para Hemodiálise/administração & dosagem , Idoso , Feminino , Humanos , MasculinoRESUMO
HFR is an integrated hemodiafiltration system that utilizes a double chamber filter to separate convection from diffusion. The ultrafiltrate is regenerated by passage through a sorbent cartridge made up of resin and activated carbon. A small percentage of patients using this technique had gastrointestinal symptoms that included nausea/vomiting, diarrhea and/or stomach cramps approximately 1-2 hours after the start of HFR. We undertook a series of investigations to try and elucidate the cause of these reactions. Since the majority of the patients were taking ACE inhibitors, attention was focused on contact phase activation. Healthy and uremic plasma were incubated with different components of the HFR circuit. The activated carbon caused a moderate activation of factor XII and production of kallikrein, while there was no activation for the lines, double filter or resin. Patients taking ACE inhibitors may be at risk for treatments involved with contact phase activation as ACE inhibitors also block the degradation of bradykinin. A new sorbent cartridge has now been developed that contains only resin.
Assuntos
Carbono/fisiologia , Hemodiafiltração/métodos , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Interações Medicamentosas , Fator XII/efeitos dos fármacos , Hemodiafiltração/efeitos adversos , Humanos , Calicreínas/efeitos dos fármacosRESUMO
Adsorbent therapies have become increasingly popular over the last several years as they permit an additional method to selectively or non-selectively remove toxins. Adsorbents offer a unique removal strategy as they have an extremely high adsorption capacity due to their great surface area. This paper describes experiments that utilized a synthetic divinylbenzene styrenic resin cartridge to remove uremic toxins from chronic renal failure patients. The resin-only cartridge was tested as an alternative after a small number of patients (primarily taking ACE inhibitors) experienced gastrointestinal problems using hemodiafiltration with on-line regeneration (HFR). Subsequent laboratory evidence suggested that the particular carbon used in the cartridge was able to activate contact phase activation. This could potentially cause problems in patients taking ACE inhibitors, as they are unable to degrade bradykinin efficiently. The resin-only cartridge was tested in at 6 centers throughout Italy and included patients that had experienced previous reactions to the carbon-resin cartridge. At the conclusion of the study, no adverse reactions were reported and the cartridge exhibited excellent removal of b2 microglobulin and angiogenin.